FDA
approval
· 2023-06-15
FDA Approved: TRIUMEQ — Supplemental Application (ViiV Healthcare Company)
Summary
FDA approved a supplemental application for Triumeq, a fixed-dose combination of abacavir sulfate, dolutegravir sodium, and lamivudine, submitted by ViiV Health…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for TRIUMEQ (ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE)